Which of the following is recently approved biosimilar drug to Neulasta?
The active ingredient found in Nyvepria is Pegfilgrastim-apgf.
Nyvepria, a biosimilar to Neulasta, is approved by the FDA to help reduce the chance of infection due to a low white blood cell count in people with non-myeloid cancer who receive anti-cancer medicines, like chemotherapy, that can cause fever and low white blood cell count. This condition, known as febrile neutropenia, is a common side effect of many types of chemotherapy and lowers the body’s ability to defend itself against infections.
Nyvepria is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Nyvepria is contraindicated in patients with a history of serious allergic reactions to Pegfilgrastim products (e.g. Neulasta) or filgrastim products (e.g. Neupogen).
Bone pain and pain in extremity are reported side effects of the drug.